Skip to content

Study · Animal study (in vivo) · rat · 2021

12 results

Self-Cross-Linked Hydrogel of Cysteamine-Grafted γ-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats.

Sun J, Xue P, Liu J, Huang L, Lin G, Ran K, Yang J, Lu C, Zhao YZ, Xu HL

ACS biomaterials science & engineering21 Sept 2021Cited by 17 (Europe PMC)

PMID34547895 (opens in a new tab)DOI10.1021/acsbiomaterials.1c00792 (opens in a new tab)PepBankPUB-34547895
Publisher pagePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with TNBS-induced colitis, rectal KPV/SH-PGA hydrogel obviously attenuated body weight loss.

    In plain wordsIn rats with colitis, KPV in a gel given rectally reduced weight loss.

    Peptide
    KPV
    Outcome
    DecreaseBody weight loss
    Study

    ratn: not reported in source

    TNBS-induced ulcerative colitis rats
    Outcome group
    Body weight · Gastrointestinal
    Studied dose
    Dose not stated · rectalAs given in this study (rat).

    Source sentences

    Summary
    The colitis symptoms including body weight loss and the disease activity index score were obviously attenuated by rectally administering the KPV/SH-PGA hydrogel.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with TNBS-induced colitis, rectal KPV/SH-PGA hydrogel obviously attenuated the disease activity index score.

    In plain wordsIn rats with colitis, KPV in a gel given rectally lowered the disease score.

    Peptide
    KPV
    Outcome
    DecreaseDisease activity index score
    Study

    ratn: not reported in source

    TNBS-induced ulcerative colitis rats
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated · rectalAs given in this study (rat).

    Source sentences

    Summary
    The colitis symptoms including body weight loss and the disease activity index score were obviously attenuated by rectally administering the KPV/SH-PGA hydrogel.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with TNBS-induced colitis, KPV/SH-PGA hydrogel treatment prevented colon shortening.

    In plain wordsIn rats with colitis, KPV in a gel prevented the colon from getting shorter.

    Peptide
    KPV
    Outcome
    DecreaseColon shortening
    Study

    ratn: not reported in source

    TNBS-induced ulcerative colitis rats
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated · rectalAs given in this study (rat).

    Source sentences

    Summary
    Besides, the KPV/SH-PGA hydrogel treatment prevented the colon shortening of TNBS-infused rats and decreased the colonic myeloperoxidase level.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats with TNBS-induced colitis, KPV/SH-PGA hydrogel treatment decreased the colonic myeloperoxidase level.

    In plain wordsIn rats with colitis, KPV in a gel lowered a colon inflammation marker.

    Peptide
    KPV
    Outcome
    DecreaseColonic myeloperoxidase level
    Study

    ratn: not reported in source

    TNBS-induced ulcerative colitis rats
    Outcome group
    Inflammation markers · Gastrointestinal
    Studied dose
    Dose not stated · rectalAs given in this study (rat).

    Source sentences

    Summary
    Besides, the KPV/SH-PGA hydrogel treatment prevented the colon shortening of TNBS-infused rats and decreased the colonic myeloperoxidase level.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats with TNBS-induced colitis, the epithelial barrier of the colon was recovered after KPV/SH-PGA hydrogel treatment.

    In plain wordsIn rats with colitis, KPV in a gel helped the colon lining barrier recover.

    Peptide
    KPV
    Outcome
    IncreaseColonic epithelial barrier morphology
    Study

    ratn: not reported in source

    TNBS-induced ulcerative colitis rats
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated · rectalAs given in this study (rat).

    Source sentences

    Summary
    The morphology of the colon including the epithelial barrier, crypt, and intact goblet cells was recovered after KPV/SH-PGA hydrogel treatment.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats with TNBS-induced colitis, the crypt morphology of the colon was recovered after KPV/SH-PGA hydrogel treatment.

    In plain wordsIn rats with colitis, KPV in a gel helped the colon crypts recover their shape.

    Peptide
    KPV
    Outcome
    IncreaseColonic crypt morphology
    Study

    ratn: not reported in source

    TNBS-induced ulcerative colitis rats
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated · rectalAs given in this study (rat).

    Source sentences

    Summary
    The morphology of the colon including the epithelial barrier, crypt, and intact goblet cells was recovered after KPV/SH-PGA hydrogel treatment.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In rats with TNBS-induced colitis, intact goblet cells were recovered after KPV/SH-PGA hydrogel treatment.

    In plain wordsIn rats with colitis, KPV in a gel helped mucus-making cells in the colon recover.

    Peptide
    KPV
    Outcome
    IncreaseColonic goblet cells
    Study

    ratn: not reported in source

    TNBS-induced ulcerative colitis rats
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated · rectalAs given in this study (rat).

    Source sentences

    Summary
    The morphology of the colon including the epithelial barrier, crypt, and intact goblet cells was recovered after KPV/SH-PGA hydrogel treatment.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In rats with TNBS-induced colitis, KPV/SH-PGA hydrogel decreased expression of tumor necrosis factor α.

    In plain wordsIn rats with colitis, KPV in a gel lowered the inflammatory signal TNF-α.

    Peptide
    KPV
    Outcome
    DecreaseTNF-α expression in colon
    Study

    ratn: not reported in source

    TNBS-induced ulcerative colitis rats
    Outcome group
    Inflammation markers · Gastrointestinal
    Studied dose
    Dose not stated · rectalAs given in this study (rat).

    Source sentences

    Summary
    Besides, the KPV/SH-PGA hydrogel decreased the expression of proinflammatory cytokines such as tumor necrosis factor α and interleukin 6.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In rats with TNBS-induced colitis, KPV/SH-PGA hydrogel decreased expression of interleukin 6.

    In plain wordsIn rats with colitis, KPV in a gel lowered the inflammatory signal IL-6.

    Peptide
    KPV
    Outcome
    DecreaseIL-6 expression in colon
    Study

    ratn: not reported in source

    TNBS-induced ulcerative colitis rats
    Outcome group
    Inflammation markers · Gastrointestinal
    Studied dose
    Dose not stated · rectalAs given in this study (rat).

    Source sentences

    Summary
    Besides, the KPV/SH-PGA hydrogel decreased the expression of proinflammatory cytokines such as tumor necrosis factor α and interleukin 6.

Studies that did not test the peptide alone3

In this study, KPV was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking KPV.

  1. 10LabNot a test of KPV aloneIn vitro (cells)Other

    The stability of KPV in the SH-PGA hydrogel was obviously enhanced, shown by retained anti-inflammatory activity after 2 h of exposure to 37 °C.

    In plain wordsIn lab tests, the gel helped KPV keep its anti-inflammatory activity after 2 hours at body temperature.

    Peptide
    KPV
    Outcome
    Not applicableKPV anti-inflammatory activity after 2 h at 37 °C in hydrogel
    Study

    n: not reported in source

    Outcome group
    Formulation, delivery and stability · Pharmacology

    Source sentences

    Summary
    Importantly, the stability of KPV in the SH-PGA hydrogel was obviously enhanced, which was presented by detecting its anti-inflammatory activity and promoting cell migration potential after 2 h of exposure to 37 °C.

    In this study, KPV was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking KPV.

  2. 11LabNot a test of KPV aloneIn vitro (cells)Other

    The stability of KPV in the SH-PGA hydrogel was obviously enhanced, shown by retained cell migration promotion after 2 h of exposure to 37 °C.

    In plain wordsIn lab tests, the gel helped KPV keep its ability to promote cell movement after 2 hours at body temperature.

    Peptide
    KPV
    Outcome
    Not applicableKPV cell migration potential after 2 h at 37 °C in hydrogel
    Study

    n: not reported in source

    Outcome group
    Formulation, delivery and stability · Pharmacology

    Source sentences

    Summary
    Importantly, the stability of KPV in the SH-PGA hydrogel was obviously enhanced, which was presented by detecting its anti-inflammatory activity and promoting cell migration potential after 2 h of exposure to 37 °C.

    In this study, KPV was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking KPV.

  3. 12LabNot a test of KPV aloneOther designOther

    Only 30% of KPV was released from the KPV/SH-PGA hydrogel within 20 min, followed by sustained release.

    In plain wordsIn lab tests, the gel released only 30% of its KPV in 20 minutes, then released it slowly.

    Peptide
    KPV
    Outcome
    Not applicableKPV release from the KPV/SH-PGA hydrogel
    Study

    n: not reported in source

    Outcome group
    Formulation, delivery and stability · Pharmacology

    Measurements

    KPV released
    30%
    within 20 min

    Source sentences

    Summary
    Only 30% of KPV was released from the KPV/SH-PGA hydrogel within 20 min, followed by a sustained-release behavior.

    In this study, KPV was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking KPV.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.